Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vanguard Health Care ETF (NY: VHT )

270.45 -1.59 (-0.58%)
Official Closing Price Updated: 8:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 203,320
Open 271.28
Bid (Size) 269.27 (9)
Ask (Size) 273.73 (9)
Prev. Close 272.04
Today's Range 269.56 - 272.34
52wk Range 250.07 - 289.14
Shares Outstanding 628,698
Dividend Yield 1.73%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hims & Hers Stock Sinks After-Hours As Weight-Loss Roadmap Gets Clouded — Retail Pounces On The Dip
On the earnings call, CEO Andrew Dudum acknowledged that the transition would be "inevitable" for patients currently on compounded semaglutide. 
Via Stocktwits
Topics Earnings
Exposures Financial
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga

Performance

YTD
+6.45%
+6.45%
1 Month
-0.50%
-0.50%
3 Month
-0.34%
-0.34%
6 Month
-5.24%
-5.24%
1 Year
+0.31%
+0.31%

More News

Read More
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide Update
Via Stocktwits
Hims & Hers Hits New Highs On At-Home Lab Testing Plans: Retail Sees More Room To Run, Analysts Divided
Via Stocktwits
Hims & Hers Stock: More Gains Ahead Or A Pullback? Most Retail Traders Bet On This Path
Via Stocktwits
US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget
Via Benzinga
Prediction: The 2 Best Vanguard Index Funds in January Will Beat the S&P 500 in 2025
Via The Motley Fool
Topics Stocks
Exposures US Equities
Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery
Via Benzinga
ETFs In Focus Post UnitedHealth's Mixed Q4 Results
Via Talk Markets
Topics ETFs Stocks / Equities
Can the 5 Worst-Performing Stock Market Sectors in 2024 Beat the S&P 500 in 2025?
Via The Motley Fool
Topics Stocks
Exposures US Equities
S&P 500 Hits 57 All-Time Highs In Record-Breaking 2024: Magnificent 7 Drive 30% Of Nasdaq's Surge
Via Benzinga
Topics Stocks
Exposures US Equities
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Via Benzinga
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
Via Benzinga
Topics Government
Exposures Political Product Safety
What Lies In Store For Healthcare ETFs In Q3 Earnings?
Via Talk Markets
Topics ETFs
Can You Lose Money Investing in ETFs? 3 Things to Know.
Via The Motley Fool
Topics ETFs
Auto Stocks, Abortion, Health Care In Spotlight At DNC: Joe Biden, UAW President, Women Affected By Roe V. Wade Decision Headline Night 1
Via Benzinga
Applying These 11 Stock Market Sectors Will Help Diversify Your Portfolio
Via Talk Markets
Topics Economy
Exposures Economy
2 Vanguard Funds Perfectly Positioned for the AI Revolution
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Want $1 Million in Retirement? 2 ETFs to Buy Now and Hold for Decades
Via The Motley Fool
Topics ETFs Retirement
Exposures Pension
Should You Buy Vanguard's Hottest Sector-Based ETF?
Via The Motley Fool
10 Best Vanguard Funds to Buy Right Now
Via The Motley Fool
Topics ETFs
Can Ocugen Stock Keep Churning Higher?
Via The Motley Fool
EXCLUSIVE: Pharma's Cloud Revolution — A $60B Market By 2030 With 1 Stock To Watch
Via Benzinga
Worried About a Market Correction? These 2 Defensive Vanguard Funds Are Pefect Safe Havens.
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.